MUCARTRIN
-
| StockNo |
Product description |
Status |
| EB0280-401-02 |
MUCARTRIN
AMPOULE 1 ML |
 |
-
- COMPOSITION:
Mucopolysaccharide 125 mg/1 ml in one ampoule
ACTION:
Mucartrin is a natural product of animal origin with a marked
chondroprotective effect. It belongs to the group of
glucoseaminoglycanes and has a particular affinity towards the
cartilage which is changed in arthrosis, accumulating it in
therapeutically effective concentrations. The preparation inhibits
the lysosomic enzymes responsible for the destruction of the
cartilage, and improves the synthesis of chondrocytes and synovial
cells.
The protective action on the articular cartilage is better
manifested during the initial stage of arthrosis, as well as when a
systematic and prolonged treatment is carried out.
The preparation has no direct analgesic effect.
INDICATIONS:
Degenerative diseases of the joints, with relatively preserved
articular cartilage and absence of inflammatory reaction (gonarthrosis,
coxarthrosis, spondylarthrosis or arthrosis with other
localizations), patellar chondropathy, postoperative treatment of
the meniscus, humeroscapular periarthritis.
CONTRAINDICATIONS:
Complete destruction of articular cartilage accompanying an
inflammatory process of the joint, increased risk of hemorrhages,
hemorrhagic diathesis, severe hypertension, insult, diabetes, before
and after surgical interventions in CNS, peptic ulcer of the stomach
and duodenum, open wounds, abortus imminens, severe diseases of
liver, kidneys and pancreas, coronary sclerosis, pregnancy,
intorelance to heparine (cross-sensitivity due to similarity in the
chemical structure); the preparation should not be given to young
people before their growth period has finished. |
SIDE EFFECTS:
Sensitization is possible, the first symptoms are: headache,
perspiration, nausea, tachycardia. Those symptoms may occur minutes
to hours after the application of the preparation and require
discontinuation of the treatment. Skin and mucosa hemorrhages may be
rarely observed. Osteoporosis may occur after prolonged treatment;
in individual cases transitory alopecia is possible, very rarely -
thrombocytopenia.
DRUG INTERACTIONS:
Mucartrine enhances the action of the anticoagulants. Simultaneous
application with cortison, acetylosalicylic acid and other
antirheumatic drugs increases the risk of gastrointestinal
hemorrhages. Mucartrine should not be mixed in one syringe with
lidocaine and other local anesthetics because of the danger of
necrosis.
DOSAGE AND ADMINISTRATION:
The preparation is applied intramuscularly or subcutaneously in a
dose of 1 ampoule, 2 times a week for 7-8 weeks, i.e. a total of 15
injections. It is recommended to repeat the treatment course 3-4
months later. Single injections may be made between the therapeutic
courses at an interval of 1-2 weeks.
MEDICINAL FORM AND PACKAGE:
Ampoules of 1 ml in packs of 10, 50 and 100.
STORAGE:
At moderate temperature (15-30° C) in a place protected from direct
sunlight.
EXPIRY:
3 (three) years.
|
